ReviewBioMed research international2016
Hepatitis E Virus in Industrialized Countries: The Silent Threat.
Review in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- A systematic review of the epidemiology of Hepatitis E virus infection in South - Eastern Asia.Virulence · 2021Pooled it
- Emerging zoonotic viral infections of occupational health importance.Pathogens and disease · 2019Pooled it
- A comprehensive review on seroepidemiology and molecular epidemiology of hepatitis E Virus in Iran.Gastroenterology and hepatology from bed to bench · 2025Review
- Investigation of hepatitis E virus seroprevalence and risk factors in hemodialysis patients.Frontiers in public health · 2025Article
- HEV Infection in Beta-Thalassemia Patients.Pathogens (Basel, Switzerland) · 2024Review
- Hepatitis E Virus (HEV) Infection in Hemodialysis Patients: A Multicenter Epidemiological Cohort Study in North-Eastern Greece.Pathogens (Basel, Switzerland) · 2023Article
- An In Silico Deep Learning Approach to Multi-Epitope Vaccine Design: A Hepatitis E Virus Case Study.Vaccines · 2023Article
- Review
- Hepatitis E Virus Seroprevalence Indicated a Significantly Increased Risk Selectively in Patients with Gastric Cancer among 17 Common Malignancies.Journal of clinical medicine · 2023Article
- Hepatitis E Virus Life Cycle.Advances in experimental medicine and biology · 2023Article
- Hepatitis E virus in pigs and the environment: An updated review of public health concerns.Narra J · 2022Review
- Seroprevalence of Anti-Hepatitis E Virus Antibodies among Patients from a Tertiary Hospital from Northeast Romania.Medicina (Kaunas, Lithuania) · 2022Article
- First Report of the HEV Seroprevalence and the Risk Factor Assessment in the West Bank, Palestine, during the Period of 2015-2017.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
- Hepatitis E Virus: An emerging enigmatic and underestimated pathogen.Saudi journal of biological sciences · 2022Review
- Epidemiology of Hepatitis E in 2017 in Bavaria, Germany.Food and environmental virology · 2021Article
- Review
- Mechanism of Cross-Species Transmission, Adaptive Evolution and Pathogenesis of Hepatitis E Virus.Viruses · 2021Review
- Towards the Improved Accuracy of Hepatitis E Diagnosis in Vulnerable and Target Groups: A Global Perspective on the Current State of Knowledge and the Implications for Practice.Healthcare (Basel, Switzerland) · 2021Review
- Swine hepatitis E virus: Cross-species infection, pork safety and chronic infection.Virus research · 2020Review
- Seroprevalence of Hepatitis E Virus in Forestry Workers from Trentino-Alto Adige Region (Northern Italy).Pathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is the main cause of acute viral hepatitis worldwide. Its presence in developing countries has been documented for decades. Developed countries were supposed to be virus-free and initially only imported cases were detected in those areas. However, sporadic and autochthonous cases of HEV infection have been identified and studies reveal that the virus is worldwide spread. Chronic hepatitis and multiple extrahepatic manifestations have also been associated with HEV. We review the data from European countries, where human, animal, and environmental data have been collected since the 90s. In Europe, autochthonous HEV strains were first detected in the late 90s and early 2000s. Since then, serological data have shown that the virus infects quite frequently the European population and that some species, such as pigs, wild boars, and deer, are reservoirs. HEV strains can be isolated from environmental samples and reach the food chain, as shown by the detection of the virus in mussels and in contaminated pork products as sausages or meat. All these data highlight the need of studies directed to control the sources of HEV to protect immunocompromised individuals that seem the weakest link of the HEV epidemiology in industrialized regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.